PAND Insider Trading Activity and SEC Form 4 Filings
PAND insider trading summary
No open-market insider purchases or sales of Pandion Therapeutics, Inc. (PAND) have been reported on SEC Form 4 in the past 12 months.
Latest PAND insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 19, 2020 | Daniel J. Becker | Director | Buy | $3.0M (197,716 @ $15.12) |
| Nov 18, 2020 | Daniel J. Becker | Director | Buy | $217K (14,197 @ $15.26) |
| Nov 17, 2020 | Daniel J. Becker | Director | Buy | $32K (2,170 @ $14.63) |
| Nov 17, 2020 | Daniel J. Becker | Director | Buy | $201K (13,027 @ $15.43) |
| Jul 21, 2020 | MVA Investors, LLC | 10% Owner | Buy | $13.0M (722,222 @ $18.00) |
| Jul 21, 2020 | Alan L Crane | Director | Buy | $628K (34,863 @ $18.00) |
| Jul 21, 2020 | Joseph Lewis | 10% Owner | Buy | $13.0M (722,222 @ $18.00) |
| Jul 21, 2020 | Christopher Fuglesang | Director | Buy | $13.0M (722,222 @ $18.00) |
| Jul 21, 2020 | Aaron I. Davis | 10% Owner | Buy | $13.0M (722,222 @ $18.00) |
| Jul 21, 2020 | Alan L Crane | Director | Buy | $252K (14,000 @ $18.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.